Skip to main content Skip to main content

Greenville Business Magazine

Biosimilars in the EU MasterClass

The market share of drug products manufactured by means of modern biotechnology is constantly increasing. In Germany, it is close to 25% in value. This means that there will be a major cost saving potential for the healthcare systems by introduction of Biosimilar competition. New therapeutic options are opened for treatment of severe medical conditions and it is obvious that this product category will become even more important in the future. Consequently, it is vital for generic pharmaceutical companies to consider extending their business scope from drug products with classical chemically synthetized API to Biosimilars. The training aims to create deeper understanding why biotechnological products – and as a consequence biosimilars – are a unique product category and what aspects have to be considered in R&D and Drug Regulatory Affairs.

Date & Time

December 1, 2020

9:00AM - 5:00PM

Add to Calendar 12/01/202009:00 AM 12/01/202005:00 PM America/New_York Biosimilars in the EU MasterClass The market share of drug products manufactured by means of modern biotechnology is constantly increasing. In Germany, it is close to 25% in value. This means... More info at www.greenvillebusinessmag.com/events/194996/biosimilars-in-the-eu-masterclass axEakIwmdzNKaowyWmiv58927

More Info

Event Website

For price, Request the agenda

Seminars & Training

Share